Suzanne Dawn Turner

This study identifies TGS1 as a methyltransferase that modifies mRNAs encoding mitochondrial proteins in AML, promoting oxidative phosphorylation and cell survival, and shows its potential as a therapeutic target.

This study uses single-cell transcriptomics to analyze T cell lymphomas, identifies developmental origins, and discovers SYK and TIM3 as potential therapeutic targets.

This study shows HDAC1 suppresses ALK-positive lymphoma growth, but systemic HDAC inhibition can still be therapeutic.

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.